|
The European Commission has granted marketing authorization for Onglyza (saxagliptin) from Bristol-Myers Squibb (BMS) and AstraZeneca to treat type 2 diabetes.
Bristol-Myers Squibb (BMS) has released its 2009 fiscal first quarter results, which show strong financial performance and the execution of two key strategic initiatives.
Bristol-Myers Squibb has signed an agreement with Nissan Chemical Industries and Teijin Pharma Limited for the development and commercialization of a selective inhibitor for the maintenance of normal sinus rhythm in patients with atrial fibrillation, currently in phase I development in Japan.
|
Bristol-Myers Squibb has reported its 2009 first quarter net earnings from continuing operations attributable to the shareholders of $638 million, compared to $647 million for the same period in 2008.
The FDA's Endocrinologic and Metabolic Drugs Advisory Committee has voted in favor of the new drug application for Onglyza from Bristol-Myers Squibb (BMS) and Astrazeneca to treat adults with type 2 diabetes, stating that the data were sufficient to rule out unacceptable cardiovascular risk relative to comparators in the program.
|
RSS 
Middle age introduces itself in many ways; one is atrial fibrillation (AF). My onset of AF seems to have coincided with a mountain bike accident in the woods of North Carolina that resulted in some cracked ribs.
The use of health IT to reduce rehospitalizations will be welcome but also disruptive, said Stephen Jencks, an independent consultant in healthcare safety during a Feb. 24 webinar on the potential use of health IT to mitigate rehospitalizations, sponsored by the Agency for Healthcare Research and Quality (AHRQ).
A new hospital breaking ground usually isn’t breaking news. But the vision of patient care at one new facility, tentatively named Palomar Medical Center West (PMC West), is currently illegal under California state law.